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ABSTRACT 
Objective: To see the frequency of non-alcoholic fatty liver disease in type II diabetic patients. To see 
biochemical derangements in NAFLD patients. Study Design: Cross-sectional study. Setting: Diabetic Research 
Centre & outpatient department Nishtar Hospital Multan. Methodology: One hundred patients of either sex 
having type II diabetes mellitus attending diabetic out-patient department Nishtar Hospital Multan were included 
in the study. A pre-designed study pro-forma was filled in relevant investigations and clinical assessments were 
carried out in all cases. All the patients underwent abdominal ultrasonography. Data were entered in SPSS-20 
and analyzed. Results: A total of 100 diabetic patients were studied. Out of these, 51 (51%) were female and 49 
(49%) were male. Mean age of the patients was 47.93 ± 8.57 years. Fifty one (51%) of the diabetic patients were 
having fatty liver. Out of these 51 patients of fatty liver, 32 (62.75%) were female and 19 (37.25%) were male. 
Fatigue was seen in 49 (53.26%), generalized weakness in 48 (52.18%), heaviness right upper abdomen in 22 
(64.70%) and pain right upper abdomen was seen in 20 (58.82%) of fatty liver patients while these were 43 
(46.74%), 44 (47.82%), 12 (35.30%) and 14 (41.18%) in non-fatty liver patients respectively. Itching was noted 
in 19 (44.18%) patients of fatty liver while it was 24 (55.82%) in non-fatty liver patients. Serum triglyceride 
level more than 160 mg/dl in 47 (92.15%) patients of fatty liver while serum cholesterol level more than 200 
mg/dl was seen in 24 (47.05%). Aspartate amino-transferase (AST) more than 35 u/l was noted in 7 (13.72%), 
alanine amino-transferase (ALT) more than 40 u/l was noted in 6 (11.76%) fatty liver patients while serum 
albumin and serum billirubin were within normal range in all fatty liver and non-fatty liver patients.  
Conclusion: Nonalcoholic fatty liver disease (NAFLD) is more commonly seen in type II diabetic patients. 
Serum triglyceride and serum cholesterol are significantly raised in NAFLD patients. Raised ALT and AST is 
not a common finding in our NAFLD study patients. Diabetic patients having heaviness or pain right upper 
abdomen with raised serum triglycerides and cholesterol should be more closely observed for NAFLD and liver 
complications. 
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INTRODUCTION 
Fatty liver is a problem which is commonly encountered in medical practice. It is defined as diffused 
accumulation of fats mainly triglycerides in the liver cells. Usually the fat contents increase more than 5% of the 
normal liver weight.
1
 If there is only accumulation of fat it is called steatosis and when this fat accumulation is 
accompanied by necro-inflammatory changes in the liver it is called steato-hepatitis. Fatty liver is divided mainly 
into two categories. 
1. Alcoholic fatty liver   2. Non-alcoholic fatty liver. 
The term non-alcoholic fatty liver disease (NAFLD) includes spectrum of changes from steatosis alone to non-
alcoholic steato-hepatitis. Diabetes mellitus is an important cause of NAFLD while other important causes are 
obesity, hepatitis C virus, hepatitis B virus, pregnancy and certain drugs especially amiodarone, synthetic 
estrogens, cortico-steroids and tamoxifen. Non-alcoholic fatty liver disease is also seen in patients with Wilson’s 
disease and haemo-chromatosis. It occurs when more fat is transported to liver from other parts of the body 
especially intestine, where accumulation of fats exceeds than its degradation and when excess carbohydrates 
delivered to the liver are converted into fatty acids. Liver damage is produced due to accumulation of fats, 
oxidative stress of mitochondria and by release of inflammatory cytokines. In diabetics NAFLD is usually 
associated with metabolic syndrome which is characterized by insulin resistance, obesity, hyper-triglyceridemia 
and hypertension and some studies describe NAFLD as hepatic component of metabolic syndrome.
2
 Various 
studies have reported variable prevalence rates of NAFLD in general population and in diabetic patients.
2-7
 It can 
occur at any age but mostly seen in age group of 40-60 years. It is commonly seen in obese persons and truncal 
obesity is main culprit. Fatty liver is usually asymptomatic but patients may present with fatigue, generalized 
weakness, jaundice, nausea, vomiting, loss of appetite, un-explained weight loss and itching. In advance stage 
patient can come with stigmata of chronic liver disease. Various biochemical derangements have also been 
described in NAFLD patients 
8
. The definite diagnosis is based upon histological examination of liver tissue 
however it is an invasive and costly procedure and is associated with complications. The present study was 
designed to see the frequency and biochemical derangements of NAFLD patients in type II diabetics.  
 
METHODOLOGY 
It was a cross-sectional study which was done using non-probable purposive sampling. A total of 100 type II 
diabetic patients were randomly selected from diabetic out patient department at Nishtar Hospital Multan. 
Informed verbal consent was taken from each patient and pre-designed proforma was filled in. Alcoholics and 
anti-HCV positive patients were excluded from the study. The presenting complaints of the patients were 
recorded and clinical assessment was done. All the patients underwent abdominal ultrasonography for detection 
of fatty liver by a sonologist. Serum cholesterol, serum triglycerides, ALT, AST, serum alkaline phosphatase, 
serum albumin, serum billirubin and anti-HCV were done in all the cases. The data were entered and analyzed 
using computer program SPSS-20.   
 
RESULTS 
A total of 100 diabetic patients were studied. Out of these, 51(51%) were female and 49 (49%) were male. Age 
varied from 40-70 years and mean age of the patients was 47.13 ± 8.57 years. Fifty one (51%) of these patients 
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were having fatty liver. Out of these 51 patients, 32 (62.75%) were female and 19 (37.25%) were male as shown 
in Fig-1. Patients presented with various complaints as shown in Table-I. Serum albumin and serum billirubin 
were normal in all the study patients while other biochemical derangements in NAFLD patients are given in 
Table-II. 
 
Table-I: Presenting complaints of fatty and non-fatty liver diabetic patients. 
Complaints Fatty liver 
patients 
Non-fatty liver 
patients 
P-value 
Fatigue 49 (53.26%) 43 (46.74%) 0.77 
Generalized weakness 48 (52.18%) 44 (47.82%) 0.78 
Heaviness right upper abdomen 22 (64.70%) 12 (35.30%) 0.01 
Pain right upper abdomen 20 (58.82%) 14 (41.18%) 0.21 
Itching 19 (44.18%) 24 (55.82%) 0.23 
Nausea 15 (60%) 10 (40%) 0.29 
Anorexia 08 (53.34%) 07 (46.86%) 0.84 
 
 
Table-II: Biochemical profile of fatty and non fatty liver diabetic patients 
Investigations Fatty liver patients Non-fatty liver 
patients 
P-value 
Serum Triglycerides 
(more than 150 mg/dl)  
47 39 0.65 
Serum Cholesterol 
(more than 200 mg/dl)  
24 18 0.18 
Serum Alkaline Phosphatase  
(more than 306 u/l)  
08 05 0.21 
AST 
(more than 35 u/l)  
07 04 0.23 
ALT 
(more than 40u/l) 
06 06 NA 
 
 
DISCUSSION 
Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder. It is mainly seen in obese and diabetic 
patients. Varying prevalence rates have been reported in various studies. A recent study from Japan in apparently 
healthy individuals has reported the prevalence of NAFLD as 29%.
3
 An Italian study reported it to be 20%.
4
 The 
frequency of NAFLD reported in general population of USA is 20%.5 A study from Karachi, Pakistan conducted 
by Luxmi et al,
2
 in 120 diabetic patients described the frequency of NAFLD as 60.8% and Akber et al from 
Saudi Arabia as 55%6 in type II diabetics and in India it is 49% among diabetics as reported by Gupta et al.7 In 
present study frequency of NAFLD is 51% which is close to the study by Gupta et al and Akber et al. It is 
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pertinent to say that we have taken abdominal ultrasonography as a tool for detection of NAFLD which can only 
detect if the fat content of the liver is more than 33% and sensitivity of ultrasonography for detection of fatty 
liver is poor if the patient has fat content less than 33% of the liver weight. The frequency of NAFLD actually 
might have been high if we had done liver biopsy for the diagnosis of NAFLD.   
Various studies describe NAFLD as asymptomatic it may be true in initial phase of NAFLD but patients may 
present with fatigue and heaviness in right upper abdomen later on. In present study fatigue was noted as chief 
complaint in 92 diabetics, out of these 49 (53.26%) were fatty liver patients. Generalized weakness was seen in 
92, out of which 48 (52.18%) were of NAFLD. Here it is difficult to say whether these complaints were purely 
due to NAFLD or underlying diabetes mellitus as our study population was type II diabetic patients. Heaviness 
right upper abdomen 22 (64.70%) and pain right upper abdomen 20 (58.82%) was seen in fatty liver patients. A 
study by Wing-kin syn et al described fatigue as an important symptom and pain right upper abdomen in 33% of 
the patients.
9
 Heaviness and pain in right upper abdomen is due to stretching of the liver capsule which is 
correlated with the amount of fat present in the liver.8,10 Diabetes mellitus is an important risk factor for NAFLD. 
It is established that diabetes mellitus through insulin resistance leads to increased free fatty acid load to the liver 
consequently high triglyceride synthesis and increased secretion of triglyceride rich very low density lipoprotein 
by the liver. Hyper-triglyceridemia is strongly correlated with NAFLD and our study also supports this. Serum 
triglycerides were raised in 92.15% of fatty liver patients. Similarly serum cholesterol was raised in 47.05% of 
patients. The study by Luxmi et al
2
 also reported raised serum triglyceride level in patients with fatty liver and 
same is the result from our study.  
Serum alkaline phosphatase was raised in 15.68% of our study patients. Raised Alkaline phosphatase has been 
described in fatty liver patients especially in old females.11 AST and ALT were raised in our study in only 7 
(13.72%)  and 6 (11.76%) fatty liver patients respectively, however raised ALT and AST have been reported in 
significant number of fatty liver patients in other studies.
12,13
 Raised ALT level is important finding in fatty liver 
patients1 while raised ALT was not seen in significant number of NAFLD patients in our study and these 
findings support the study by Luxmi et al.
2
 Normal ALT has also been reported in NAFLD by other studies.
9
 
Mofrad
14
 reported that histologic spectrum is not significantly different in patients with the raised or normal 
ALT and normal values did not confirm freedom from steato-hepatitis. 
 
CONCLUSION 
Nonalcoholic fatty liver disease (NAFLD) is more commonly seen in type II diabetic patients. Serum 
triglyceride and serum cholesterol are significantly raised in NAFLD patients. Raised ALT and AST is not a 
common finding in our NAFLD study patients. Diabetic patients having heaviness or pain right upper abdomen 
with raised serum triglycerides and cholesterol should be more closely observed for NAFLD and liver 
complications. 
Suggestions: 
1. Type II diabetic patients should also be monitored for the development of NAFLD and its 
complications. 
2. Anti-HCV positive type II diabetic patients having fatty liver should be more carefully looked for 
sequelae of fatty liver. 
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